Does Desire Come Back After You Stop?

Start with the uncomfortable answer

Nobody knows, because nobody has studied it.

There is no cohort, no trial arm and no registry analysis following what happens to sexual desire in women after they stop a GLP-1. The only direct published evidence connecting these drugs to sexual function in women is a single case report — one patient, written up by a dermatology and sexology group, explicitly because the effect "is not well known."¹

One case is a reason to look. It is not a finding, and anyone quoting it as though it establishes a pattern is over-reading it.

So this page does the honest thing instead: it lays out what withdrawal research does establish, and reasons carefully from there.

What is actually established about stopping

The clearest data comes from the STEP 1 trial extension, which followed 327 participants for a year after treatment ended.²

• Over the treatment year, semaglutide produced a mean 17.3% weight loss against 2.0% on placebo.
• In the year after withdrawal, participants regained 11.6 percentage points of what they had lost.
• That left a net loss of 5.6% from where they started, roughly two years in.
• Cardiometabolic improvements — the blood-pressure and lipid gains — reverted toward baseline for most measures.

In plain terms: about two-thirds of the loss came back, and the metabolic benefits largely went with it. The authors' own conclusion was that this confirms obesity behaves as a chronic condition and that ongoing treatment is needed to hold the improvements.²

Why that matters for desire

Here is the reasoning, and it is reasoning rather than evidence.

If desire changed while you were on the drug, there are only a few candidate explanations, and this site has written about that confound at length: the medication itself, the weight loss, or the change in how you felt in your own body. Those three move together on the way down, which is precisely why they are so hard to separate.

Stopping pulls them apart in a specific and informative way. The drug leaves your system quickly. The weight comes back slowly, over about a year. So whatever happens to desire in that gap is genuinely informative for you, even though nobody has aggregated it across a population.

• If desire shifts within weeks of stopping, that points toward the drug.
• If it tracks the weight coming back over months, that points to the body-image and physical route.
• If it does not move at all, that is worth knowing too — it means the thing you attributed to the medication probably was not the medication.

You are not going to get this answer from a trial in the next few years. You can get it from your own timeline, which is the unsatisfying but accurate advice.

What the qualitative work suggests

The nearest useful evidence is descriptive. A qualitative study interviewed eight participants — all women, mean age 42 — who had been on semaglutide or tirzepatide for six to eighteen months. The themes were feeling more capable, becoming more deliberate about food, and a marked quieting of the mental noise around eating.³

That last theme is the one worth holding onto. If a substantial part of what changed for you was mental bandwidth rather than hormones, then what returns after stopping may be the noise rather than the desire. Those are different problems with different answers, and conflating them is how women end up asking for the wrong help.

What to do with all this

• Do not stop a medication to test a theory about your libido. The regain data is unambiguous, and the trade is a bad one.
• If you are stopping anyway, for cost or supply or side effects, note where your desire sits at the time. You are creating the only dataset that will ever be about you.
• Give it more than a few weeks. The weight moves over roughly a year, so a four-week verdict is not a verdict.
• Bring the timeline to a clinician rather than the conclusion. "It changed three weeks after I stopped" is useful. "The drug ruined my libido" closes the conversation.
• Treat anyone confidently telling you what happens after stopping with suspicion. There is one published case. That is the entire direct literature.